Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Restore Immune Competence in Treatment-Resistant Metastatic Castration-Resistant Prostate Cancer
2016-000579-26Phase 2Terminated
- Sponsor
- Ospedale Santa Croce e Carle
- Start
- Sep 2021
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide and aldesleukin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Ospedale Santa Croce e Carle. Primary endpoint: Objective response rate. Started Sep 2021; status: terminated.
02
Drugs
cyclophosphamidealdesleukin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2016-000579-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000579-26.